When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZN - Viela Bio IPO: At Phase 3 Of Development With Positive Results
AstraZeneca PLC
With product candidates acquired from AstraZeneca (AZN) and MedImmune, Viela Bio (VIE) is clinical-stage biotechnology to be followed carefully. Besides, at Phase 3 of development, the company could deliver positive results in 2020, which may make the share price run. After the IPO, we expect Viela to have an enterprise value between $180 and $310 million. With that, in our opinion, savvy individuals will try to acquire shares at an enterprise value of $200 million.